References
- MasumoriNTsukamotoTHoritaHα1-blocker tamsulosin as initial treatment for patients with benign prostatic hyperplasia: 5-year outcome analysis of a prospective multicenter studyInt J Urol201320442142822989348
- CollinsGNRaabGMHehirMKingBGarrawayWMReproducibility and observer variability of transrectal ultrasound measurements of prostate volumeUltrasound Med Biol1995219110111058849824
- TakeiR-IIkegakiIShibataKTsujimotoGAsanoTNaftopidil, a novel α1-adrenoceptor antagonist, displays selective inhibition of canine prostatic pressure and high affinity binding to cloned human α1-adrenoceptorsJpn J Pharmacol199979444745410361884
- GarimellaPSFinkHAMacDonaldRWiltTJNaftopidil for the treatment of lower urinary tract symptoms compatible with benign prostatic hyperplasia (review)Cochrane Database Syst Rev20094CD00736019821408
- MasumoriNNaftopidil for the treatment of urinary symptoms in patients with benign prostatic hyperplasiaTher Clin Risk Manag2011722723821753885
- HaraNMizusawaTObaraKTakahashiKThe role of naftopidil in the management of benign prostatic hyperplasiaTher Adv Urol20135211111923554846
- FukutaFMasumoriNA review of naftopidil for treatment of lower urinary tract symptoms suggestive of benign prostatic hyperplasiaCurr Bladder Dysfunct Rep2015102160169
- CastiglioneFBenigniFBrigantiANaftopidil for the treatment of benign prostate hyperplasia: a systematic reviewCurr Med Res Opin201430471973224188134
- MasumoriNHashimotoJItohNTsukamotoTGroupTSShort-term efficacy and long-term compliance/treatment failure of the alpha1 blocker naftopidil for patients with lower urinary tract symptoms suggestive of benign prostatic hyperplasiaScand J Urol Nephrol200741542242917853040
- KawachiYSakuraiTSugimuraSLong-term treatment and prognostic factors of alpha 1-blockers for lower urinary tract symptoms associated with benign prostatic hyperplasia: a pilot study comparing naftopidil and tamsulosin hydrochlorideScand J Urol Nephrol2010441384520095868
- YokoyamaTWatanabeTSaikaTNatural course of lower urinary tract symptoms following discontinuation of alpha-1-adrenergic blockers in patients with benign prostatic hyperplasiaInt J Urol200714759860117645601
- McConnellJDRoehrbornCGBautistaOMMedical Therapy of Prostatic Symptoms (MTOPS) Research GroupThe long-term effect of doxazosin, finasteride, and combination therapy on the clinical progression of benign prostatic hyperplasiaN Engl J Med2003349252387239814681504
- RoehrbornCGSiamiPBarkinJCombAT Study GroupThe effects of combination therapy with dutasteride and tamsulosin on clinical outcomes in men with symptomatic benign prostatic hyperplasia: 4-year results from the CombAT studyEur Urol201057112313119825505